参附注射液对失血性休克防治的研究进展

Research Progress on the Prevention and Treatment of Hemorrhagic Shock with Shenfu Injection

摘要: 失血性休克(Hemorrhagic Shock, HS)是多种原因造成大量失血所致有效循环血量减少、组织灌注不足、细胞代谢紊乱和器官功能受损的病理生理过程。失血性休克的损失机制复杂多样，主要涉及组织细胞缺氧、氧代动力学异常、微循环功能障碍、能量代谢异常、炎症反应、凝血功能障碍、内脏器官的继发性损害等一系列病理生理变化机制。目前的研究显示，参附注射液(SFI)对失血性休克治疗有独特优势，可通过多途径、多靶点进行干预，从而降低病死率及改善预后。本文分别从传统医学以及现代医学的角度探讨了参附注射液在治疗失血性休克中的药理作用，为临床上使用参附注射液更好地防治失血性休克提供理论依据。

Abstract: Hemorrhagic Shock (HS) is a pathological process caused by a significant blood loss from various reasons, which leads to a reduction in effective circulating blood volume, insufficient tissue perfusion, cellular metabolic disorders, and organ dysfunction. The pathogenesis of hemorrhagic shock is complex and diverse, mainly involving a series of pathological and physiological changes such as tissue cell hypoxia, abnormal oxygen kinetics, microcirculatory dysfunction, energy metabolism disorders, inflammatory responses, coagulation dysfunction, and secondary damage to visceral organs. Current research indicates that Shenfu Injection (SFI) has unique advantages in the treatment of hemorrhagic shock. It can intervene through multiple pathways and targets, thereby reducing mortality and improving prognosis. This article discusses the pharmacological effects of Shenfu Injection in the treatment of hemorrhagic shock from the perspectives of traditional and modern medicine, providing a theoretical basis for the better prevention and treatment of hemorrhagic shock with Shenfu Injection in clinical practice.